Insilico Medicine is dramatically accelerating drug candidate development by integrating artificial intelligence with laboratory research, a process that now takes about a year, according to CEO Alex Zhavoronkov. The Hong Kong-listed company has achieved a record nine-month timeline for its fastest program to reach candidate nomination, a stark contrast to the typical four-and-a-half years required by conventional methods. This expedited timeline, however, focuses on early discovery and candidate selection, with subsequent stages like clinical trials, manufacturing, and regulatory review remaining as distinct phases.
AI’s Revolution in Candidate Selection
At the core of Insilico’s approach is generative AI, employed to pinpoint biological targets, conceptualize novel drug molecules, and rigorously assess which compounds warrant further laboratory investigation. The company reports that its AI-driven programs typically achieve preclinical candidate nomination within 12 to 18 months, following the synthesis and testing of a refined library of 60 to 200 molecules. This workflow seamlessly blends AI-generated designs with human expertise for review and experimental validation. While laboratory experiments are indispensable for confirming biological activity and drug properties, Insilico’s AI-augmented process significantly reduces the number of synthesized molecules that need to be tested, although direct comparative data against non-AI programs are not yet publicly available.
Since 2021, Insilico has successfully generated 31 preclinical candidates, with 13 programs already receiving investigational new drug clearances, paving the way for human studies. The company’s strategic global footprint includes AI research hubs in Montreal and Abu Dhabi, complemented by extensive experimental validation and laboratory scale-up operations in China, particularly at its Shanghai facility which has embraced automation in biological sampling and compound screening. This division of labor ensures that AI model development and evaluation are handled by international teams, while on-the-ground researchers in Shanghai manage the critical biological testing and scale-up processes.
Zhavoronkov credits China’s robust research infrastructure, competitive operating costs, and evolving regulatory landscape as significant contributors to the shortened development cycles. He estimates that pharmaceutical companies leveraging research laboratories in China can shave approximately two years off traditional candidate development timelines. China’s role in drug discovery is rapidly evolving beyond the manufacturing of generic ingredients, with international pharmaceutical giants increasingly collaborating with Chinese laboratories, contract research organizations, clinical trial centers, and biotech firms. This shift is underscored by reports of clinical development in China being up to three times faster and approximately half the cost of equivalent work in Europe, with drug candidates typically reaching the Chinese market in five to seven years, compared to eight to ten years in Western markets. Further accelerating this progress, China introduced a streamlined 30-working-day review pathway in 2025 for eligible Class I innovative drug clinical trial applications, with provisions for a 60-working-day review for more complex cases.
“We now compete with Chinese pharmaceutical companies on timelines, and with traditional biotechnology companies in the West on novelty,” Zhavoronkov stated, highlighting Insilico’s dual competitive edge. The company has already established R&D agreements with industry leaders such as Eli Lilly and Japan’s Takeda. Moreover, a proposed strategic alliance with Taiwan-based Bora Pharmaceuticals could potentially exceed $2.5 billion upon finalization of agreements.
Despite its operational presence in China, Zhavoronkov noted that over 90% of Insilico’s revenue originates from Western pharmaceutical companies, attributing this trend to the lower reimbursement rates for highly novel drugs within China’s national insurance system. Geopolitical considerations also influence Insilico’s sales of its software products within China, with the company electing to limit such sales while still planning for further expansion of its research operations in Shanghai.
Rentosertib Advances Towards Phase III Trials
Insilico’s drug candidate Rentosertib is now progressing towards Phase III trials for idiopathic pulmonary fibrosis, a progressive lung scarring disease. The company utilized its AI platform to identify the drug’s biological target and subsequently design and optimize its molecular structure. The Phase III study, slated to commence enrollment in July 2026 across 47 centers in China, will involve 320 participants. This crucial trial will evaluate Rentosertib against a placebo over a 52-week period, with the primary endpoint focusing on the annual rate of decline in forced vital capacity, a key lung function metric. The trial’s ClinicalTrials.gov record, updated on July 7, indicated it was not yet recruiting, with enrollment projected to begin in August 2026 and primary completion estimated by October 2029.
Rentosertib having successfully completed a Phase IIa study, the upcoming Phase III trial represents a significant scale-up of testing in a larger patient population over an extended duration. It is important to underscore that candidate nomination remains an early-stage achievement. The journey to market approval necessitates completion of preclinical testing, human trials, manufacturing validation, and rigorous regulatory review. Currently, empirical data demonstrating a higher success rate for AI-designed drugs in later-stage clinical trials are not definitively established.
A 2024 analysis of AI-native biotechnology pipelines indicated Phase I success rates between 80% and 90%, with Phase II success rates hovering around 40%, largely aligning with historical industry benchmarks. However, the study’s authors cautioned that the limited number of Phase II programs within the analyzed dataset made it difficult to ascertain any definitive AI-driven improvement in later-stage clinical success. This analysis was based on publicly available pipeline data and did not include direct comparisons of otherwise identical AI-supported versus conventionally developed drug programs.
Insilico’s track record includes the generation of 31 preclinical candidates and the securing of 13 investigational new drug clearances. Rentosertib marks its first program to reach the pivotal Phase III stage, while none of the company’s experimental medicines have yet achieved commercial approval.
Automation Reshapes Biotech Workforce Dynamics
The integration of AI and laboratory robotics is also instigating significant shifts in Insilico’s staffing requirements. Zhavoronkov anticipates that approximately 40% of the company’s software-focused workforce could be affected by automation, though he clarified this is not an announced reduction and does not represent a blanket impact across the entire biotechnology sector. Insilico, with a workforce of around 400 employees, is strategically retraining its laboratory scientists and software engineers to manage AI evaluation systems, sophisticated automated equipment, and robotic platforms. This retraining initiative prioritizes AI benchmarking and the operation of robotic systems as the company progressively automates more research and software functions.
Original article, Author: Samuel Thompson. If you wish to reprint this article, please indicate the source:http://aicnbc.com/24103.html
